English

RegenoCELL Therapeutics, Inc.

EDGAR

Annual report (10-K) · filed 2012-05-25

45 filing records in this dataset, filed from 2003-03-03 to 2012-05-25. Explore the available filing history and original sources.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

162 thousand USD

2011-09-30 · USD

Exact inputs and evidence

Revenue: 162365 USD Source

Operating margin

-194.4%

2011-09-30 · %

Exact inputs and evidence

Operating Income: -315639 USD Source
Revenue: 162365 USD Source

Operating cash flow

-326 thousand USD

2011-09-30 · USD

Exact inputs and evidence

Operating Cash Flow: 150882 USD Source
Operating Cash Flow: 477305 USD Source

Free cash flow

-326 thousand USD

2011-09-30 · USD

Exact inputs and evidence

Operating Cash Flow: 150882 USD Source
Operating Cash Flow: 477305 USD Source
Capital Expenditure: 0 USD Source
Capital Expenditure: 0 USD Source

Cash and cash equivalents: 181 thousand USD 2011-09-30 Source
Exact value

181139 USD
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

790 thousand USD

2010-10-01 – 2011-09-30

Exact inputs and evidence

Revenue: 910048 USD · 2010-01-01 – 2010-12-31 Source
Revenue: 738855 USD · 2010-01-01 – 2010-09-30 Source
Revenue: 262225 USD · 2011-01-01 – 2011-03-31 Source
Revenue: 194220 USD · 2011-04-01 – 2011-06-30 Source
Revenue: 162365 USD · 2011-07-01 – 2011-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2012-05-25.

Financial data available through: 2010-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2010-12-31
Operating income: 2 of 11 periods available· newest 2010-12-31
Net income: 3 of 11 periods available· newest 2010-12-31
Operating cash flow: 3 of 11 periods available· newest 2010-12-31
Capital expenditure: 3 of 11 periods available· newest 2010-12-31
Total assets: 3 of 11 periods available· newest 2010-12-31
Total liabilities: 3 of 11 periods available· newest 2010-12-31
Current assets: 3 of 11 periods available· newest 2010-12-31
Current liabilities: 3 of 11 periods available· newest 2010-12-31
Cash and cash equivalents: 3 of 11 periods available· newest 2010-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+USD 910,048

Prior period

USD 0

2009-01-01 – 2009-12-31
Current period

USD 910,048

2010-01-01 – 2010-12-31

Exact inputs and evidence

910048 − 0 = 910048 USD

0 USD · 2009-01-01 – 2009-12-31
Inspect prior input Prior source
910048 USD · 2010-01-01 – 2010-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · RegenoCELL Therapeutics, Inc. · 2010-12-31 RegenoCELL Therapeutics, Inc. (edgar:1221749) Year-over-year change in Revenue: 910048 USD Concept: fundies:Revenue Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1221749?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 910048 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1221749/0001144204-11-030288.txt#4131 Input fundies:Revenue: 0 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1221749/0001144204-11-030288.txt#4131
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 3.83 million

Prior period

−USD 228,663

2009-01-01 – 2009-12-31
Current period

−USD 4.06 million

2010-01-01 – 2010-12-31

Exact inputs and evidence

-4057131 − -228663 = -3828468 USD

-228663 USD · 2009-01-01 – 2009-12-31
Inspect prior input Prior source
-4057131 USD · 2010-01-01 – 2010-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · RegenoCELL Therapeutics, Inc. · 2010-12-31 RegenoCELL Therapeutics, Inc. (edgar:1221749) Year-over-year change in Net income: -3828468 USD Concept: fundies:NetIncome Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1221749?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -4057131 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1221749/0001144204-11-030288.txt#5296 Input fundies:NetIncome: -228663 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1221749/0001144204-11-030288.txt#5296
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 106,223

Prior period

−USD 58,587

2009-01-01 – 2009-12-31
Current period

−USD 164,810

2010-01-01 – 2010-12-31

Exact inputs and evidence

-164810 − -58587 = -106223 USD

-58587 USD · 2009-01-01 – 2009-12-31
Inspect prior input Prior source
-164810 USD · 2010-01-01 – 2010-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · RegenoCELL Therapeutics, Inc. · 2010-12-31 RegenoCELL Therapeutics, Inc. (edgar:1221749) Year-over-year change in Operating cash flow: -106223 USD Concept: fundies:OperatingCashFlow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1221749?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -164810 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1221749/0001144204-11-030288.txt#5462 Input fundies:OperatingCashFlow: -58587 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1221749/0001144204-11-030288.txt#5462
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-100%

Prior period

USD 3,099

2009-01-01 – 2009-12-31
Current period

USD 0

2010-01-01 – 2010-12-31

Exact inputs and evidence

0 − 3099 = -3099 USD

3099 USD · 2009-01-01 – 2009-12-31
Inspect prior input Prior source
0 USD · 2010-01-01 – 2010-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · RegenoCELL Therapeutics, Inc. · 2010-12-31 RegenoCELL Therapeutics, Inc. (edgar:1221749) Year-over-year change in Capital expenditure: -3099 USD Concept: fundies:CapitalExpenditure Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1221749?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 0 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1221749/0001144204-11-030288.txt#5496 Input fundies:CapitalExpenditure: 3099 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1221749/0001144204-11-030288.txt#5496
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2010 2010-01-01 – 2010-12-31

Revenue USD 910,048 100% of revenue
Operating costs Derived USD 4.71 million 518% of revenue
Operating income −USD 3.8 million −418% of revenue
Tax, interest and other Derived USD 255,261 28% of revenue
Net income −USD 4.06 million −446% of revenue

Cash

Operating cash flow −USD 164,810 −18% of revenue
Capital expenditure USD 0 0% of revenue
Free cash flow Derived −USD 164,810 −18% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2008 Not shown: operating income or net income is not reported.
2009 Not shown: operating income or net income is not reported.
2010 Operating loss: operating costs were 518% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2008 2008-01-01 – 2008-12-31	0	Unavailable	Unavailable	Unavailable	-48532	-41262 Derived	Source 2008-01-01 – 2008-12-31: 0 USD Inspect Revenue Open source 2008-01-01 – 2008-12-31: -48532 USD Inspect Net Income Open source 2008-01-01 – 2008-12-31: -41262 USD Inspect Operating Cash Flow Open source 2008-01-01 – 2008-12-31: 0 USD Inspect Capital Expenditure Open source
2009 2009-01-01 – 2009-12-31	0	223526 Derived	-223526	5137 Derived	-228663	-61686 Derived	Source 2009-01-01 – 2009-12-31: 0 USD Inspect Revenue Open source 2009-01-01 – 2009-12-31: -223526 USD Inspect Operating Income Open source 2009-01-01 – 2009-12-31: -228663 USD Inspect Net Income Open source 2009-01-01 – 2009-12-31: -58587 USD Inspect Operating Cash Flow Open source 2009-01-01 – 2009-12-31: 3099 USD Inspect Capital Expenditure Open source
2010 2010-01-01 – 2010-12-31	910048	4711918 Derived	-3801870	255261 Derived	-4057131	-164810 Derived	Source 2010-01-01 – 2010-12-31: 910048 USD Inspect Revenue Open source 2010-01-01 – 2010-12-31: -3801870 USD Inspect Operating Income Open source 2010-01-01 – 2010-12-31: -4057131 USD Inspect Net Income Open source 2010-01-01 – 2010-12-31: -164810 USD Inspect Operating Cash Flow Open source 2010-01-01 – 2010-12-31: 0 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 910K 2010

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20082008-12-31	Revenue	0	Revenue: 0 Open source
20092009-12-31	Revenue	0	Revenue: 0 Open source
20102010-12-31	Revenue	910048	Revenue: 910048 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20082008-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20092009-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20102010-12-31	Year over year	No prior comparable period	Revenue: 910048 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -417.8% 2010

Net margin -445.8% 2010

Free cash flow margin -18.1% 2010

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
2008-12-31	Operating margin	Not reported	Revenue: 0 Open source
20092009-12-31	Operating margin	Not reported	Operating Income: -223526 Open source Revenue: 0 Open source
20102010-12-31	Operating margin	-417.8%	Operating Income: -3801870 Open source Revenue: 910048 Open source
20082008-12-31	Net margin	Not reported	Net Income: -48532 Open source Revenue: 0 Open source
20092009-12-31	Net margin	Not reported	Net Income: -228663 Open source Revenue: 0 Open source
20102010-12-31	Net margin	-445.8%	Net Income: -4057131 Open source Revenue: 910048 Open source
20082008-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -41262 Open source Capital Expenditure: 0 Open source
20092009-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -58587 Open source Capital Expenditure: 3099 Open source
20102010-12-31	Free cash flow margin	-18.1%	Revenue: 910048 Open source Operating Cash Flow: -164810 Open source Capital Expenditure: 0 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -164.8K 2010

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20082008-12-31	Operating cash flow	-41262	Operating Cash Flow: -41262 Open source
20092009-12-31	Operating cash flow	-58587	Operating Cash Flow: -58587 Open source
20102010-12-31	Operating cash flow	-164810	Operating Cash Flow: -164810 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -164.8K 2010

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20082008-12-31	Free cash flow	-41262	Operating Cash Flow: -41262 Open source Capital Expenditure: 0 Open source
20092009-12-31	Free cash flow	-61686	Operating Cash Flow: -58587 Open source Capital Expenditure: 3099 Open source
20102010-12-31	Free cash flow	-164810	Operating Cash Flow: -164810 Open source Capital Expenditure: 0 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

1,374% 2010

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20082008-12-31	Liabilities / assets	1,390.1%	Total Liabilities: 125110 Open source Total Assets: 9000 Open source
20092009-12-31	Liabilities / assets	437%	Total Liabilities: 458746 Open source Total Assets: 104972 Open source
20102010-12-31	Liabilities / assets	1,374%	Total Liabilities: 4705108 Open source Total Assets: 342432 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.11× 2010

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20082008-12-31	Current assets / current liabilities	0×	Current Assets: 0 Open source Current Liabilities: 6457 Open source
20092009-12-31	Current assets / current liabilities	0.22×	Current Assets: 102079 Open source Current Liabilities: 458746 Open source
20102010-12-31	Current assets / current liabilities	0.11×	Current Assets: 191452 Open source Current Liabilities: 1717837 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2008 2008-01-01 – 2008-12-31	−USD 48,532 Exact value Exact value: -48532 USD 2008-01-01 – 2008-12-31: -48532 USD Inspect Net Income Open source Share or cite Citation for Net Income · RegenoCELL Therapeutics, Inc. · 2008-12-31 RegenoCELL Therapeutics, Inc. (edgar:1221749) Net Income: -48532 USD Concept: fundies:NetIncome Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1221749/explain?concept=fundies%3ANetIncome&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:NetIncome: -48532 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1221749/0001144204-10-023746.txt#5402 The citation records this snapshot. The page link may show a newer release later.	−USD 41,262 Exact value Exact value: -41262 USD 2008-01-01 – 2008-12-31: -41262 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · RegenoCELL Therapeutics, Inc. · 2008-12-31 RegenoCELL Therapeutics, Inc. (edgar:1221749) Operating Cash Flow: -41262 USD Concept: fundies:OperatingCashFlow Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1221749/explain?concept=fundies%3AOperatingCashFlow&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -41262 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1221749/0001144204-10-023746.txt#6302 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2008-01-01 – 2008-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · RegenoCELL Therapeutics, Inc. · 2008-12-31 RegenoCELL Therapeutics, Inc. (edgar:1221749) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1221749/explain?concept=fundies%3ACapitalExpenditure&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1221749/0001144204-10-023746.txt#6354 The citation records this snapshot. The page link may show a newer release later.	−USD 41,262 Calculation and evidence -41262 − 0 USD Exact free cash flow: -41262 USD 2008-01-01 – 2008-12-31: -41262 USD · Inspect Operating Cash Flow · Source 2008-01-01 – 2008-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · RegenoCELL Therapeutics, Inc. · 2008-12-31 RegenoCELL Therapeutics, Inc. (edgar:1221749) Free cash flow: -41262 USD Concept: free-cash-flow Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1221749?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -41262 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1221749/0001144204-10-023746.txt#6302 Input fundies:CapitalExpenditure: 0 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1221749/0001144204-10-023746.txt#6354 The citation records this snapshot. The page link may show a newer release later.
2009 2009-01-01 – 2009-12-31	−USD 228,663 Exact value Exact value: -228663 USD 2009-01-01 – 2009-12-31: -228663 USD Inspect Net Income Open source Share or cite Citation for Net Income · RegenoCELL Therapeutics, Inc. · 2009-12-31 RegenoCELL Therapeutics, Inc. (edgar:1221749) Net Income: -228663 USD Concept: fundies:NetIncome Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1221749/explain?concept=fundies%3ANetIncome&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:NetIncome: -228663 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1221749/0001144204-11-030288.txt#5296 The citation records this snapshot. The page link may show a newer release later.	−USD 58,587 Exact value Exact value: -58587 USD 2009-01-01 – 2009-12-31: -58587 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · RegenoCELL Therapeutics, Inc. · 2009-12-31 RegenoCELL Therapeutics, Inc. (edgar:1221749) Operating Cash Flow: -58587 USD Concept: fundies:OperatingCashFlow Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1221749/explain?concept=fundies%3AOperatingCashFlow&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -58587 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1221749/0001144204-11-030288.txt#5462 The citation records this snapshot. The page link may show a newer release later.	USD 3,099 Exact value Exact value: 3099 USD 2009-01-01 – 2009-12-31: 3099 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · RegenoCELL Therapeutics, Inc. · 2009-12-31 RegenoCELL Therapeutics, Inc. (edgar:1221749) Capital Expenditure: 3099 USD Concept: fundies:CapitalExpenditure Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1221749/explain?concept=fundies%3ACapitalExpenditure&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3099 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1221749/0001144204-11-030288.txt#5496 The citation records this snapshot. The page link may show a newer release later.	−USD 61,686 Calculation and evidence -58587 − 3099 USD Exact free cash flow: -61686 USD 2009-01-01 – 2009-12-31: -58587 USD · Inspect Operating Cash Flow · Source 2009-01-01 – 2009-12-31: 3099 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · RegenoCELL Therapeutics, Inc. · 2009-12-31 RegenoCELL Therapeutics, Inc. (edgar:1221749) Free cash flow: -61686 USD Concept: free-cash-flow Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1221749?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -58587 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1221749/0001144204-11-030288.txt#5462 Input fundies:CapitalExpenditure: 3099 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1221749/0001144204-11-030288.txt#5496 The citation records this snapshot. The page link may show a newer release later.
2010 2010-01-01 – 2010-12-31	−USD 4.06 million Exact value Exact value: -4057131 USD 2010-01-01 – 2010-12-31: -4057131 USD Inspect Net Income Open source Share or cite Citation for Net Income · RegenoCELL Therapeutics, Inc. · 2010-12-31 RegenoCELL Therapeutics, Inc. (edgar:1221749) Net Income: -4057131 USD Concept: fundies:NetIncome Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1221749/explain?concept=fundies%3ANetIncome&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:NetIncome: -4057131 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1221749/0001144204-11-030288.txt#5296 The citation records this snapshot. The page link may show a newer release later.	−USD 164,810 Exact value Exact value: -164810 USD 2010-01-01 – 2010-12-31: -164810 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · RegenoCELL Therapeutics, Inc. · 2010-12-31 RegenoCELL Therapeutics, Inc. (edgar:1221749) Operating Cash Flow: -164810 USD Concept: fundies:OperatingCashFlow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1221749/explain?concept=fundies%3AOperatingCashFlow&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -164810 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1221749/0001144204-11-030288.txt#5462 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2010-01-01 – 2010-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · RegenoCELL Therapeutics, Inc. · 2010-12-31 RegenoCELL Therapeutics, Inc. (edgar:1221749) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1221749/explain?concept=fundies%3ACapitalExpenditure&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1221749/0001144204-11-030288.txt#5496 The citation records this snapshot. The page link may show a newer release later.	−USD 164,810 Calculation and evidence -164810 − 0 USD Exact free cash flow: -164810 USD 2010-01-01 – 2010-12-31: -164810 USD · Inspect Operating Cash Flow · Source 2010-01-01 – 2010-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · RegenoCELL Therapeutics, Inc. · 2010-12-31 RegenoCELL Therapeutics, Inc. (edgar:1221749) Free cash flow: -164810 USD Concept: free-cash-flow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1221749?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -164810 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1221749/0001144204-11-030288.txt#5462 Input fundies:CapitalExpenditure: 0 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1221749/0001144204-11-030288.txt#5496 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

45 filings · 0 latest values · 0 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001221749, 1221749, edgar:1221749

Also known as GOOD BUDDYS COFFEE EXPRESS INC

RegenoCELL Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Trailing twelve months

Revenue

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2010 2010-01-01 – 2010-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation